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Background: Identification of tumour antigens is crucial for the development of vaccination strategies against hepatocellular
carcinoma (HCC). Most studies come from eastern-Asia, where hepatitis-B is the main cause of HCC. However, tumour antigen
expression is poorly studied in low-endemic, western areas where the aetiology of HCC differs.
Methods: We constructed tissue microarrays from resected HCC tissue of 133 patients. Expression of a comprehensive panel of
cancer-testis (MAGE-A1, MAGE-A3/4, MAGE-A10, MAGE-C1, MAGE-C2, NY-ESO-1, SSX-2, sperm protein 17), onco-fetal
(AFP, Glypican-3) and overexpressed tumour antigens (Annexin-A2, Wilms tumor-1, Survivin, Midkine, MUC-1) was determined by
immunohistochemistry.
Results: A higher prevalence of MAGE antigens was observed in patients with hepatitis-B. Patients with expression of more
tumour antigens in general had better HCC-specific survival (P¼ 0.022). The four tumour antigens with high expression in HCC
and no, or weak, expression in surrounding tumour-free-liver tissue, were Annexin-A2, GPC-3, MAGE-C1 and MAGE-C2,
expressed in 90, 39, 17 and 20% of HCCs, respectively. Ninety-five percent of HCCs expressed at least one of these four
tumour antigens. Interestingly, GPC-3 was associated with SALL-4 expression (P¼ 0.001), an oncofetal transcription factor
highly expressed in embryonal stem cells. SALL-4 and GPC-3 expression levels were correlated with vascular invasion, poor
differentiation and higher AFP levels before surgery. Moreover, patients who co-expressed higher levels of both GPC-3 and SALL-
4 had worse HCC-specific survival (P¼ 0.018).
Conclusions:We describe a panel of four tumour antigens with excellent coverage and good tumour specificity in a western area,
low-endemic for hepatitis-B. The association between GPC-3 and SALL-4 is a novel finding and suggests that GPC-3 targeting may
specifically attack the tumour stem-cell compartment.
Hepatocellular carcinoma (HCC) is a leading cause of cancer-
related death, with over half a million deaths per year worldwide
(El-Serag et al, 2001; Jemal et al, 2011). HCC is more prevalent in
eastern Asia (Jemal et al, 2011) where hepatitis-B (HBV) accounts
for 65% of HCC cases (Perz et al, 2006). In contrast, western
Europe is a low-endemic area where HBV is not the main cause of
HCC (Perz et al, 2006), and HCC is often diagnosed in non-
cirrhotic livers (Verhoef et al, 2004; Witjes et al, 2012). However, it
is estimated that the incidence of HCC is expected to continue to
rise significantly in western Europe and North America due to
the hepatitis C virus infections during the 1960s and 1970s
(IARC, 2011).
Primary treatment for early-stage disease includes resection,
local ablation and, in selected cases, liver transplantation. However,
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only 20% of patients are candidates for curative procedures
(El-Serag et al, 2008). Once the cancer is advanced cure is no
longer possible and median survival is a dismal 6–8 months, which
can be extended to 10–13 months with the addition of sorafenib, a
tyrosine kinase inhibitor (Llovet et al, 2008; Abou-Alfa et al, 2010).
Recognition of the important role of the immune system in
cancer surveillance and elimination (Zou, 2005) has led to the
development of various immunotherapeutic strategies against
cancer (Mellman et al, 2011). One such strategy, cancer
vaccination, holds great promise, as has been recently demon-
strated in prostate cancer (Kantoff et al, 2010a,b). In HCC, cancer
vaccine trials have shown promising results, in particular after local
therapy to prevent relapses (Kuang et al, 2004; Lee et al, 2005; Peng
et al, 2005a). However, despite the promise of cancer vaccines,
success has been limited due to a number of factors. One of these is
the proper identification of tumour antigens. Important require-
ments for inclusion of tumour antigens in therapeutic vaccines are
immunogenicity, prevalence of expression within the cancer
population, tumour tissue specificity and biologic significance
(Cheever et al, 2009; Lang et al, 2009; Kvistborg et al, 2013).
Multiple studies have described the expression of tumour
antigen panels in HCC, but the vast majority of these studies were
conducted in east Asian populations (Chen et al, 2001; Luo et al,
2002; Peng et al, 2005b; Nakamura et al, 2006; Sera et al, 2008;
Shirakawa et al, 2009; Yan et al, 2011; Yorita et al, 2011; Liang et al,
2013; Xia et al, 2013) where the aetiology of HCC is predominately
related to HBV. Very few such studies have been performed in
western, low-endemic areas (Riener et al, 2009).
Tumour tissue specificity refers to the predominant, most
preferably exclusive, expression of the tumour antigen in cancer
and not in normal tissues (Kvistborg et al, 2013). A strict
interpretation of this requirement would limit tumour antigens to
antigens resulting from somatic mutations, chromosomal translo-
cations resulting in neo-antigens, or viral-derived antigens.
However, exome sequencing has recently shown that somatic
mutation patterns in HCC are strongly variable between individual
patients and therefore not suitable for design of off-the-shelf
therapeutic vaccines (Fujimoto et al, 2012). The most promising
alternative tumour antigens are cancer-testis antigens, which are
exclusively expressed in germ cells but not in other normal tissues
(Hofmann et al, 2008), and oncofetal antigens, expressed primarily
during embryogenesis but not broadly in adult humans (AFP,
Glypican-3). Both types of antigens are aberrantly expressed in
various types of cancer. In addition, self-antigens that are
overexpressed in cancer (Survivin, Wilms tumor-1, Midkine and
Annexin-A2) are also considered tumour antigens, and several
clinical trials are underway in HCC and other cancers, targeting
these types of overexpressed self-antigens. Many of the existing
studies in HCC do not include tumour antigen expression in the
corresponding surrounding tumour-free liver (TFL) compartment
and thus tissue specificity cannot be assessed.
In this study, we used immunohistochemistry on tissue
microarrays (TMAs) to examine, on the protein level, the
expression pattern in HCC of a comprehensive panel of 15
tumour antigens belonging to different categories, including the
cancer testis antigens MAGE-A1, MAGE-A3/4, MAGE-A10,
MAGE-C1, MAGE-C2, NY-ESO-1, Sperm Protein 17 (SP17) and
SSX-2, the oncofetal proteins AFP and Glypican-3 (GPC-3),
the overexpressed tumour antigens Annexin-A2, Wilms tumour-1
(WT-1), Survivin, Midkine (MDK) and the glycoprotein MUC-1.
All these antigens have previously demonstrated immunogenicity
in human studies. In addition, we tested for the expression
of SALL-4, a transcription factor involved in the maintenance of
embryonic and cancer stem cells (Zeng et al, 2014). SALL-4 has
recently been shown to be expressed in an HCC subtype with stem-
cell like features and to be associated with poor prognosis
(Oikawa et al, 2013; Yong et al, 2013b; Zeng et al, 2014). The
goal of the study was to identify a panel of biologically relevant
tumour antigens with (a) broad expression in a western European
population of HCC patients and (b) specific expression in
the tumour tissue with no, or little, expression in surrounding
TFL tissue.
MATERIALS AND METHODS
Patient population and tissue samples. Archived formalin-fixed
paraffin-embedded tissue samples from 133 patients who under-
went hepatic resection (n¼ 94) or liver transplantation (n¼ 39) for
HCC in our centre, between July 2004 and October 2013, were
used for this study. Clinicopathologic characteristics are shown in
Table 1. All patients had undergone procedures with curative
intent and none had received systemic therapy before resection or
transplantation. Patients with evidence of residual cancer after
resection were excluded. Informed consent for the use of tissue for
research purposes was obtained from all patients.
TMA construction. Three 0.6-mm cores were taken from the
tumorous area of 133 patients and two 0.6-mm cores were taken
from the corresponding TFL tissue of 105 of these patients.
The tumorous as well as the TFL areas with vital tissue were
marked by an experienced pathologist using archived H&E glass
slides. In each TMA we included cores of testis, placenta, tonsil,
ovary, stomach, prostate, bladder, kidney, lung and liver as control
tissues. The TMAs were made using a Beecher automated tissue-
arrayer ATA-27 (Beecher Instruments, Sun Prairie, WI, USA).
Immunohistochemistry. Immunohistochemistry was performed
on 4-mm thick sections mounted on Superfrost Plus slides
(Erie Scientific LLC, Portsmouth, NH, USA). The sections were
deparaffinized and rehydrated. Endogenous peroxidase activity was
blocked with 0.3% H2O2 for 15min. Antigen retrieval was
performed in a microwave for 10min using the appropriate
antigen retrieval buffer for each antigen (Table 2). After serum
block, primary antibodies were applied at 41C overnight. The
primary antibodies (Table 2) were carefully selected to be
monoclonal (with the exception of AFP and SP17) and to have
been validated in scientific literature. HRP-conjugated anti-mouse
or anti-rabbit polymer secondary antibody (Envision, DAKO,
Glostrup, Denmark) was then applied for 1 h, followed by
diaminobenzadine (DAB) as the chromogen detection method.
The slides were stained with haematoxylin followed by dehydra-
tion. The above protocol was used for all antibodies with the
exception of GPC-3 and AFP where an automated BenchMark
ULTRA instrument (Ventana Medical Systems, Inc, Tuscon, AZ,
USA) was used in a clinical laboratory setting. Scoring was
performed by two independent investigators and differences
resolved by mutual agreement. Intensity was scored as either
none, weak, moderate or strong, while percentage of positive cells
was scored as o5%, 5–25%, 25–75% and475%. For a staining to
be considered positive at least 5% of cells had to be stained.
Negative controls consisted of omission of the primary antibody
and appropriate positive control tissues were used for all
antibodies. H-scores were calculated by multiplying the intensity
score (0 to 3) with the level of % of positive cells where 1¼o5%,
2¼ 5–25%, 3¼ 25–75% and 4¼475%.
Statistical analysis. The association of the expression level of
tumour antigens with the various subgroup populations was
analysed using the w2-test. The association of the tumour antigen
expression with the clinicopathologic parameters was analysed
using the w2-tests for categorical variables and the Student’s t-test
for continues variables. Survival analyses were performed using
the Kaplan–Meier method and the log-rank test. Univariate
and multivariate hazard ratios, 95% confidence intervals and
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corresponding P-values were obtained using Cox regression
analysis. The statistical analysis was performed using the SPSS 21
software (IBM Corp., Armonk, NY, USA).
RESULTS
Tumour antigen expression in HCC and TFL tissue.
The expression of the 15 tumour antigens in both tumour and
TFL tissue is shown in Table 3. No expression of SSX-2 and
MUC-1 was observed, although the antibodies properly stained
testis (seminiferous duct cells) and gastric control tissue,
respectively. The prevalence of expression of MAGE-A3/4,
NY-ESO-1, AFP, MAGE-A1 and MAGE-A10 was low (o10% of
patients), while increasing numbers of HCC showed expression of
MAGE-C1, MAGE-C2, GPC-3, MDK, Survivin, WT-1, SP17 and
Annexin-A2 (prevalence ranging from 17 to 90%, Table 3).
However, the overexpressed self-antigens MDK, Survivin, WT-1
and SP17 showed equal expression in tumours and in TFL tissues.
Thus, the tumour antigens with the highest differential expression
level between tumour tissue and TFL tissue are Annexin-A2 (90.2
vs 37.1%), GPC-3 (39.1 vs 0%), MAGE-C2 (19.5 vs 0%) and
MAGE-C1 (17.3 vs 0%). This conclusion did not change when we
analysed only the 105 patients with paired tumour and TFL tissue
as compared to the entire cohort of 133 patients. Representative
immunohistochemical stainings of these four tumour antigens in
HCC and TFL tissue are shown in Figure 1, while representative
immunohistochemical stainings of all the tumour antigens can be
seen in Supplementary Figure 1. The distribution of intensity and
the percentage of stained cells in tumour tissue, and in the case of
Annexin-A2 in TFL tissue, are shown in Figure 2. MAGE-C1 and
GPC-3 showed cytoplasmic expression in tumour cells, while
MAGE-C2 showed nuclear expression in tumour cells. Annexin-
A2 showed membranous and cytoplasmic expression in hepato-
cytes in HCC and TFL tissue, and stained sinusoidal endothelium.
These expression patterns are in agreement with previous
observations in HCC (Riener et al, 2009; Longerich et al, 2011;
Liang et al, 2013). Only hepatocyte and not sinusoidal staining was
scored for Annexin-A2. Moreover, Annexin-A2 expression showed
a weaker intensity in the hepatocytes of the TFL tissue than
the corresponding tumour cells (Figures 2D and E). Looking at
aetiologic factors, there was a significantly higher prevalence of
expression of MAGE-A3/4 (P¼ 0.011), MAGE-A1 (P¼ 0.034) and
MAGE-C1 (P¼ 0.008) in patients with HBV infection compared
with patients without HBV infection, while MAGE-C2 (P¼ 0.264)
and GPC-3 (P¼ 0.334) showed a statistical trend towards higher
expression in patients with HBV infection (Figure 3).
Tumour antigen index. As in previous studies (Liang et al, 2013)
a tumour antigen index (TAA) was calculated based on the total
number of antigens co-expressed in a given tumour tissue. Patients
were grouped based on whether they co-expressed 0–2 tumour
antigens, 3–6 tumour antigens or 7–9 tumour antigens. No patients
co-expressed more than 9 out of the 15 tumour antigens. The
higher the TAA index the better the HCC-specific survival was
(P¼ 0.020, Supplementary Figure 2). In multivariable analysis this
was an independent prognostic factor for HCC-specific survival
(Table 4).
Co-expression patterns of MAGE-C1, MAGE-C2, GPC-3 and
Annexin-A2. Further analysis was performed on the four antigens
with the greatest differences in expression between tumour
and TFL tissue, namely MAGE-C1, MAGE-C2, GPC-3 and
Annexin-A2. Expression of at least one of these antigens
was observed in tumour tissues of 95% of patients, while 48% of
patients expressed only one antigen, 30% expressed two antigens,
11% expressed three antigens and 6% expressed four antigens
(Figure 4A). Co-expression of these antigens in individual patients
is shown in Figure 4B. Ninety-two percent of patients express,
individually, or in combination, Annexin-A2 and GPC-3. Of the
patients that do not express Annexin-A2 or GPC-3, 3% express
MAGE-C1 or MAGE-C2. In 11% of patients MAGE-C1 and
MAGE-C2 add a second tumour antigen to patients that otherwise
express only one antigen, either GPC-3 or Annexin-A2. Finally, in
10% of patients MAGE-C1 and MAGE-C2 add a third antigen to
patients that co-express GPC-3 and Annexin-A2. Interestingly,
MAGE-C1 and MAGE-C2 are significantly and strongly
co-expressed in tumours of our HCC patients (Po0.001, Pearson’s
correlation coefficient¼ 0.68). This panel of four antigens also
covers tumours of most HBV-negative patients (95%), of which
52% expressed one antigen, 29% expressed two antigens, 9%
Table 1. Patient characteristics
Characteristics No. of patients 133 (%)
Age (years)
Median 60.4
Range 22.9–86.6
Gender
Male 95 (71.4)
Female 38 (38.6)
Ethnicity
Western-European 103 (77.4)
Non western-Europeana 30 (22.7)
Aetiologyb
No known liver disease 37 (27.8)
Hepatitis B 24 (18.0)
Alcohol abuse 22 (16.5)
Hepatitis C 18 (13.5)
Cryptogenic cirrhosis 10 (7.5)
NASH 9 (6.8)
Hemochromatosis 5 (3.8)
Primary biliary cirrhosis 3 (2.3)
Other 5 (3.8)
Viral hepatitis statusc
Hepatitis B positived 30 (22.6)
Hepatitis C positivee 19 (14.3)
Cirrhosis present
Yes 69 (51.9)
No 64 (48.1)
Tumour differentiation
Good 43 (32.6)
Moderate 66 (50.0)
Poor 23 (17.4)
Vascular invasion
Yes 71 (62.3)
No 43 (37.7)
Number of lesions
Single 90 (67.7)
Multiple 43 (32.3)
Size of largest lesion
Median 4.5 cm
Range 0.5–25
AFP level before resection
Median 8 mg l1
Range 1–63 000
aNon-western European patients are from East-Europe (n¼ 3), Suriname (n¼ 7), Middle-
East (n¼ 8), Sub-Sahara Africa (n¼ 3) and South-East Asia (n¼ 9). See Supplementary
Table 1.
bPatients with more than one aetiologic factor were listed based on the most dominant
cause of liver disease.
cThree patients had both hepatitis B and hepatitis C.
dHBsAg(þ ) and/or anti-HBc positive.
eAnti-HCV positive.
Tumour antigen expression in HCC BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2015.92 1913
expressed three antigens and 5% expressed four antigens. Together,
these data show that this panel of four tumour antigens may
be suitable for vaccination studies in HCC patients in western
low-endemic areas.
Expression of SALL-4 and co-expression with GPC-3. SALL-4 is
a transcription factor involved in the maintenance of embryonic
and cancer stem cells (Zeng et al, 2014) and has recently been
shown to be expressed in an HCC subtype with stem-cell like
features associated with poor prognosis (Oikawa et al, 2013; Yong
et al, 2013b; Zeng et al, 2014). In our study SALL-4 nuclear
expression was seen in 26% of tumours and in none (0%) of the
TFL samples. Like in previous studies (Zeng et al, 2014), SALL-4
was more frequently expressed in tumours of patients with HBV
infection (40 vs 22%, P¼ 0.05) and its expression was correlated
with poor differentiation (P¼ 0.002) and higher AFP levels before
surgery (P¼ 0.007), while there was a trend towards correlation
with vascular invasion (P¼ 0.081). Interestingly, there was a
significant correlation between SALL-4 expression and GPC-3
expression (P¼ 0.001, Pearson’s correlation coefficient¼ 0.29,
Figure 5). While neither SALL-4 or GPC-3 were individually
associated with HCC-specific survival, there was a trend towards
worse HCC-specific survival in patients co-expressing both GPC-3
and SALL-4 (P¼ 0.190, Supplementary Figure 3a). In addition,
when the strength of the staining was taken into consideration in
the form of the H-score (intensity x % of positive cells) patients
who co-expressed high levels of both SALL-4 (H-score42) and
GPC-3 (H-score43) had a significantly worse HCC-specific
survival (P¼ 0.018, Supplementary Figure 3b). This was an
independent prognostic factor in multivariate analysis (Table 4).
Relationship of individual tumour antigen expression with
known prognostic markers. Of all the tumour antigens tested,
GPC-3 was the one most strongly associated with known
prognostic factors. Specifically, GPC-3 was associated with poor
tumour differentiation (P¼ 0.004), the presence of vascular
invasion (P¼ 0.002) and higher AFP before resection (P¼ 0.03).
DISCUSSION
The aim of this study was to identify a panel of tumour antigens
suited for immunotherapeutic approaches, such as vaccination, for
HCC in western-European, low-endemic areas, where HBV
infection is not the main aetiology of HCC and where the
diagnosis is often made in non-cirrhotic livers (Verhoef et al, 2004;
Witjes et al, 2012). In our cohort, only 23% of patients were HBV
Table 2. Primary antibodies
Antigens Primary antibody source Clone Retrieval buffer Dilution References
MAGE-A1 Santa Cruz Biotechnology (Santa Cruz, CA, USA) MA454 Tris EDTA 1 : 50 (Jungbluth et al, 2000)
MAGE-A3/4 Professor G.C. Spagnolia 57B Tris EDTA 1 : 100 (Landry et al, 2000)
MAGE-A10 Professor G.C. Spagnolia 3GA11 Citric acid 1 : 10 (Schultz-Thater et al, 2011)
NYESO-1 Santa Cruz Biotechnology E978 Tris EDTA 1 : 50 (Vaughan et al, 2004)
SSX-2 Professor A.G. van Kesselb E3AS Tris EDTA 1 : 25 (dos Santos et al, 2000)
MAGE-C1 Santa Cruz Biotechnology CT7-33 Tris EDTA 1 : 50 (Xia et al, 2013)
MAGE-C2 Professor Boquan Yinc CT-10 Tris EDTA 1 : 100 (Zhuang et al, 2006)
MUC-1 Sanbio (Uden, The Netherlands) MA695 Citric acid 1 : 100 (Langner et al, 2004)
AFP Dako Polyclonal Tris EDTA 1 : 400 Dakod
GPC-3 Santa Cruz Biotechnology 1G12 Tris EDTA 1 : 200 (Shirakawa et al, 2009)
Annexin-A2 BD Biosciences (Breda, The Netherlands) 5 Tris EDTA 1 : 200 (Yee et al, 2007)
WT-1 Novus Biologicals (Abingdon, UK) 6F-H2 Tris EDTA 1 : 400 (Nakatsuka et al, 2006)
Survivin Santa Cruz Biotechnology D-8 Tris EDTA 1 : 50 (Brennan et al, 2008)
MDK GeneTex (Irvine, CA, USA) EP1143Y Citric acid 1 : 400 (Liang et al, 2013)
SP17 Proteintech (Manchester, UK) Polyclonal Citric acid 1 : 100 Proteinteche
SALL-4 Santa Cruz Biotechnology EE-30 Tris EDTA 1 : 50 (Yong et al, 2013b)
aMAGE-A3/A4 and MAGE-A10 antibodies graciously provided by Professor Giulio Spagnoli, Department of Surgery, Research Laboratory, University Hospital Basel, Basel, Switzerland (Landry
et al, 2000; Schultz-Thater et al, 2011).
bSSX-2 antibody graciously provided by Professor Ad Geurts van Kessel, Department of Human Genetics University Hospital Nijmegen, 6500 HB Nijmegen, The Netherlands (dos Santos et al,
2000).
cMAGE-C2 antibody graciously provided by Professor Boquan Yin, Department of Immunology, Fourth Military Medical University, Xi’an 710032, PR China (Zhuang et al, 2006).
dhttp://www.dako.com/nl/ar38/p102130/prod_products.htm Accessed 8-9-14.
ehttp://www.ptglab.com/PView/SPA17-Antibody-13367-1-AP-PVIEW.htm Accessed 8-9-14.
Table 3. Tumour antigen expression
Antigens
% Positive
stainings in tumour
tissue (n¼133)
% Positive
stainings in TFL
tissue (n¼105)
SSX-2 0 0
MUC-1 0 0
MAGE-A3/4 3.0 0
NYESO-1 3.8 0
AFP 6.8 0.9
MAGE-A10 7.5 0
MAGE-A1 9.8 0
MAGE-C1 17.3 0
MAGE-C2 19.5 0
GPC-3 39.1 0
MDK 57.7 64.4
Survivin 79.5 91.1
WT-1 85.6 84.6
SP17 87.0 88.0
Annexin-A2 90.2 37.1
Abbreviation: TFL¼ tumour-free liver
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positive, 14% HCV-positive and 48% had no liver cirrhosis.
In addition, 77.4% of our patients are of western-European decent.
Supplementary Table 1 describes the hepatitis-B status of patients
per patient region of origin. Groups other that western-European
are too small for subgroup analysis of antigen expression.
The observed prevalence of expression of testis and oncofetal
antigens was generally lower than previous studies reported. Most
of these previous studies have been conducted in East Asia where
HBV infection is the most prevalent cause of HCC and the
majority of HCC patients have liver cirrhosis. For example, a
previous east Asian study reported that 36% of patients expressed
MAGE-C1 (Xia et al, 2013), while we found only 17% expression.
Supporting the association between cancer testis antigens and HBV
infection, we found increased prevalence of MAGE-A1, MAGE-
A3/4 and MAGE-C1 expression in HBV-positive patients. The
prevalence of MAGE-C1 expression in HCC tissues in our HBV
positive patients was similar to that reported by Xia et al (2013)
(32% in HBV positive vs 13% in HBV negative patients). The only
other large western study that has examined several of these
antigens by immunohistochemistry is by Riener et al (2009) who
studied 146 HCC patients from Switzerland, of which only 12%
had HBV. In that study MAGE-C1 expression was found expressed
in 12% of patients, NY-ESO-1 in 2% and MAGE-A3/4 in 0%,
results that are similar to our findings. Likewise, expression of the
oncofetal protein GPC-3 was found in 61–84% of patients in four
Asian studies with HBV positivity ranging between 25 and 85%
(Shirakawa et al, 2009; Yan et al, 2011; Yorita et al, 2011; Liang
et al, 2013), and all these studies showed evidence of increased
GPC-3 expression in the HBV-positive patients compared with
the HBV-negative patients. In our study GPC-3 expression was
found in 39% of all patients but in 48% of HBV-positive patients.
Another explanation for the relatively low prevalence of
tumour antigen expression observed in our study is that many
previous studies have used RT-PCR measuring mRNA expression
(Chen et al, 2001; Luo et al, 2002; Peng et al, 2005b), while we have
measured protein expression by immunohistochemistry. In fact,
large discrepancies between tumour antigen expression in HCC
by RT-PCR and immunohistochemistry have been reported.
For example, Nakamura et al (2006) found 18/41 of HCC samples
(43%) expressing NY-ESO-1 by RT-PCR while only 3 (7%)
expressed the protein. It is likely that protein expression rather
than RNA expression is a reliable predictor of suitability of tumour
antigens for vaccination studies.
While the absence of MUC-1 expression in HCC is in
agreement with previous work (Cao et al, 1999), the absence of
SSX-2 in our study (0%) is in contrast to the study by Liang et al
(2013) where a prevalence of 75% was reported. The use of
different antibody clones may be one explanation. Clone 4D10,
used in the Liang et al (2013) study, was not tested in TFL samples
to examine tumour specificity. In addition, two studies (Luo et al,
2002; Wu et al, 2006) using RT-PCR have shown expression in 2/
21 and 13/36 HCC-patients, respectively, indicating that it is
unlikely that the true protein expression level of SSX-2 in HCC is
very high. Finally, despite the lack of staining in tumour or TFL
tissue, antibody clone E3AS, which we used, showed proper
staining of positive control seminiferous duct cells in testis tissue
(Supplementary Figure 1).
AFP was found to be expressed in few HCC samples (7%) in our
study. While an incidence as low as 2% has been reported
(Ferrandez-Izquierdo and Llombart-Bosch, 1987) most studies
show expression of AFP in around 17–50% of HCC tumours
(Ganjei et al, 1988; Brumm et al, 1989; Minervini et al, 1997; Tsuji
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Figure 1. Representative stainings for tumour tissue and TFL tissue with negative and positive controls for MAGE-C1, MAGE-C2, GPC-3 and
Annexin-A2. Strong tumour cell stainings for MAGE-C1, MAGE-C2, GPC-3 and Annexin-A2 are seen in the leftmost column. The second column
shows lack of staining in the corresponding TFL tissues with the exception of Annexin-A2 where staining of sinusoids is seen. The third column
shows the corresponding negative controls and the last column shows the corresponding positive controls, which are testis tissue for MAGE-C1
and MAGE-C2, fetal liver tissue for GPC-3 and pancreatic cancer tissue for Annexin-A2.
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et al, 1999; Lau et al, 2002). To ensure accuracy of AFP staining in
our study AFP expression was determined twice, under clinical
laboratory conditions (automated BenchMark ULTRA instru-
ment), which yielded identical results. On further examination
AFP expression was strongly correlated with serum AFP level
before resection (Po0.001). Of the patients with a serum AFP
4400 mg l 1 29% expressed AFP in their tumours vs only 3% in
patients with a serum AFP o400 mg l 1 (P¼ 0.001). This
correlation of AFP serum levels with tumour AFP expression has
been demonstrated before (Li et al, 2011). In our cohort, however,
only 17% of our patients had an AFP value above 400 mg l 1. Thus,
one possible explanation for the low incidence of AFP staining is
the relative low number of patients with high serum AFP levels.
Indeed, most contemporary series report high AFP serum levels
(4400 mg l 1) in 27 to 45% of patients undergoing resection
(Wang et al, 2009; Ma et al, 2013; Liu et al, 2014).
While MDK, SP17, WT-1 and Survivin were expressed in the
majority of tumours, we observed similar expression in adjacent
TFL tissues, suggesting they might be unsuitable for vaccination
studies in HCC due to lack of tumour-tissue specificity.
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Indeed these four antigens have been shown to be expressed in
tissues other than cancer (Scharnhorst et al, 2001; Deguchi et al,
2002; Kannangai et al, 2005; Monma et al, 2013), or other than
cancer and testis in the case of SP17 (Lacy and Sanderson, 2001;
Frayne and Hall, 2002). Although in some reports the expression of
MDK, SP17 and WT-1 has been shown to be lower in TFL tissue
than in HCC tissue (Koide et al, 1999; Sera et al, 2008; Xia et al,
2013; Zhu et al, 2013), in the case of Survivin another report
corroborates the equal or higher TFL, compared with tumour,
expression (Chau et al, 2007).
It has been previously shown by Liang et al (2013), that the
higher the number of tumour antigens expressed by a given
tumour the better the survival is. The hypothesis is that the higher
the number of tumour antigens present the more the immunologic
targets available to the immune system. In our study, in agreement
with Liang et al (2013), we show that the higher the number of
tumour antigens present in a given tumour the better the HCC-
specific mortality is (Table 4, Supplementary Figure 2). While our
findings are supportive of the above hypothesis, further validation
and experimentation is necessary to prove the concept.
Therapeutic vaccination with a panel of tumour antigens, as
opposed to a single antigen, would have the advantage of better
coverage of the target tumour cell population as well as covering
patients who express different antigens in their tumours. The panel
that we selected (MAGE-C1, MAGE-C2, GPC-3 and Annexin-A2)
covers 95% of patients, with nearly 50% of them expressing at least
two antigens. In addition, as in many patients expression of each
individual antigen is limited to only 5–25% of tumour cells
(Figure 2), targeting multiple antigens per patient may be needed
to realise a successful clinical outcome. In addition, our antigen
panel lacks, for the most part, expression in TFL tissue, which is an
advantage, as it may reduce unwanted side effects. Even in the
case of Annexin-A2, where a sizable proportion of TFL samples
expressed the antigen (37%), the level of expression was
much lower than that in the corresponding tumour samples
(Figure 2D and E).
Biologically, GPC-3, a heparin sulphate proteoglycan expressed
during embryogenesis, has been shown to be a poor prognostic
factor in multiple studies (Shirakawa et al, 2009; Yan et al, 2011;
Yorita et al, 2011; Liang et al, 2013). We confirm that GPC-3
expression is associated with higher serum AFP level (Yorita et al,
2011; Liang et al, 2013), worse tumour differentiation (Shirakawa
et al, 2009; Yan et al, 2011; Yorita et al, 2011) and the presence of
vascular invasion (Yorita et al, 2011). The immunogenicity of
GPC-3 has been well demonstrated, and a phase I clinical cancer
vaccine trial has already demonstrated tolerability and biologic
efficacy (Sawada et al, 2012). In addition, gene expression profiling
has shown that GPC-3 is significantly overexpressed in CD90þ
HCC stem cells (Ho et al, 2012), suggesting that targeting GPC-3
may enable eradication of the tumour stem cell compartment. Our
newly reported association of GPC-3 with SALL-4 strengthens the
notion that GPC-3 is involved in stem cell biology in HCC. In fact,
we show that patients who co-express high levels of both GPC-3
and SALL-4 have worse HCC-specific survival (Supplementary
Figure 3b), indicating that the co-expression is biologically
significant. However, it should be noted that strong co-expression
is a relatively infrequent event occurring in 7.5% of patients. While
other studies (Yan et al, 2011; Yong et al, 2013a) have shown worse
overall survival for patients expressing individually GPC-3 or
SALL-4 we did not show such an association. This is likely due to
the fact that our study is smaller in size and was not designed to
test the presence of biomarkers in HCC. In fact, when considering
patients with higher GPC-3 staining, or patients with higher
SALL-4 staining, statistical trends towards worse HCC-specific
survival are apparent and consistent with the smaller size of our
cohort (Supplementary Figure 3c and d). Finally, although both
GPC-3 and SALL-4 are considered possible therapeutic targets in
HCC (Filmus and Capurro, 2013; Yakaboski et al, 2014),
information on immunogenicity of SALL-4 is lacking. Therefore,
further research on immunogenicity of SALL-4 is needed before we
can suggest to include SALL-4 in a therapeutic vaccine.
Annexin-A2, a calcium-dependent phospholipid binding
protein, is involved in membrane formation, exocytosis and
interaction with the extracellular matrix (Gerke and Moss, 2002).
It is overexpressed in HCC (Yu et al, 2007; Mohammad et al, 2008)
and multiple other cancers (Zhang et al, 2012), is involved in
invasion and metastasis (Zhao et al, 2010), and immunogenicity
has been demonstrated (Liu et al, 2011; Zheng and Jaffee, 2012).
Table 4. Cox proportional Hazard regression analysis of patients’ overall survival
Univariate Multivariate
Variables HR 95% CI P-value HR 95% CI P-value
AFP 4400 mg l1 2.867 1.176–6.992 0.021 2.682 0.947–7.601 0.063
43 vs p3 lesions 4.438 1.594–12.353 0.004 3.771 1.276–11.141 0.016
TAA index
0–2 vs 3–6 antigens 0.266 0.076–0.925
0.042
0.238 0.062–0.909
0.033
0–2 vs 7–9 antigens 0.070 0.007–0.711 0.048 0.004-0.557
High H-score for both GPC-3 and SALL-4 3.119 1.154–8.430 0.025 3.674 1.120–12.055 0.032
Abbreviations: CI¼ confidence interval; HR¼ hazard’s ratio; TAA¼ tumour antigen index.
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Our results are in agreement with Liu et al (2013) in that Annexin-
A2 is expressed in the majority of patients with HCC and
expression is significantly more pronounced in the tumour cells as
compared with the surrounding TFL tissue. Our study is one of the
very few to examine the protein level expression of Annexin-A2 in
a ‘western’ cohort. Longerich et al (2011) demonstrated Annexin-
A2 expression in HCC in a small western European patient cohort,
but did not study expression in TFL tissue.
MAGE-C1 and MAGE-C2 are involved in embryogenesis, their
expression is known to be reactivated in various cancers, and they
are known immunogens (Li et al, 2004). The strong co-expression
between MAGE-C1 and MAGE-C2 was not surprising, as the two
genes are located close to each other on chromosome X (q27) and
are likely translated together. However, despite their strong
co-expression, a little less than half of positive cases expressed
either one of the two antigens alone indicating a potential value in
including both of these antigens in a tumour vaccine.
In conclusion, we show that there are aetiological differences in
tumour antigen expression in HCC. In addition, we describe a
panel of four antigens, MAGE-C1, MAGE-C2, GPC-3 and
Anexxin-A2, which combine several favourable characteristics for
future vaccination studies in patients in western low-endemic
areas, such as combined coverage for the majority of patients, as
well as tumour specificity. Finally, we demonstrate for the first time
a relationship between GPC-3 and SALL-4 expression, which
further substantiates that targeting GPC-3 may enable eradication
of the HCC tumour stem-cell compartment.
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